Document is current

Article History

Received: 30 April 2025

Accepted: 27 November 2025

First Online: 14 January 2026

Declarations

:

: The authors declare the following competing interests: G.R., L.F. and N.H. are employees at AlveoliX and N.H. holds equity in AlveoliX AG. The remaining authors (L.J., J.C., J.L., P.A., C.B., J..H, A.O. and P.F.) are employees and/or shareholders of AstraZeneca.

: Human cell material provided by AlveoliX was anonymized and used with patient’s consent and ethical approval from Kantonale Ethikkommission Bern. Rat and cynomolgus monkey studies from where data is presented, were performed at Charles River Edinburgh in the UK and thus conducted under the UK Home Office Act (project license number PBAD559F8) by the issue of license under the animals (Scientific Procedures) Act 1986. The regulations conform to EU Directive 2010/63/EU and achieve the standard of care required by the US Department of Health and Human Services’ Guide for the Care and Use of Laboratory Animals.